|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.93|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for UCB SA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)
Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).
Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.